Sobrerol Composition for Ischemic Stroke Infarction Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for ischemic stroke are limited in efficacy and have significant time constraints, with no fundamental solution for reducing infarction size or addressing brain tissue damage effectively.
Innovation Solution
A pharmaceutical and food composition containing sobrerol or its pharmaceutically acceptable salts, which provide neuroprotective effects and reduce infarction size by administering a compound represented by Chemical Formula 1, offering brain protection against ischemic brain tissue damage.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current antithrombotic agents (tPA) are used to treat ischemic stroke, then thrombus dissolution is achieved, but the treatment window is limited to 4-5 hours and hemorrhagic stroke risk increases
Solution Approach 1:
The patent applies preliminary action by administering sobrerol before ischemic stroke occurs or at the very early stage. The composition prevents neuronal death and reduces infarction size through pre-protective mechanisms, including upregulation of Bcl-2 and downregulation of Bax expressions, thereby extending the effective treatment window beyond the conventional 4-5 hour limit of tPA
2Reliability
If tPA is administered to dissolve thrombus, then blood flow is restored, but hemorrhagic stroke and allergic reactions occur as side effects
Solution Approach 1:
The patent converts the harmful effect of ischemia into a beneficial protective mechanism. Sobrerol triggers endogenous protective pathways, including activation of PI3K/Akt signaling and upregulation of anti-apoptotic proteins (Bcl-2), transforming the threat of neuronal death into a protective state that reduces infarction without causing hemorrhage
3Ease of operation
If calcium influx into neurons is allowed during ischemia, then neurotransmission continues, but intracellular homeostasis is lost and neuronal damage occurs
Solution Approach 1:
The patent applies parameter changes by modulating calcium homeostasis parameters during ischemia. Sobrerol maintains intracellular calcium levels within safe ranges, preventing the pathological calcium influx that triggers apoptosis. This is achieved through regulation of calcium channels and pumps, thereby preserving neuronal function while preventing damage
4Ease of operation
If excitory neurotransmitters are released during ischemia, then neuronal signaling is maintained, but metabolic demands increase and hypoxia worsens
Solution Approach 1:
The patent applies partial action by selectively maintaining essential neuronal signaling while suppressing excessive neurotransmitter release. Sobrerol modulates glutamate release and NMDA receptor activity, preserving necessary neural communication while reducing the excessive metabolic burden that exacerbates hypoxia during ischemia
Data Source
AI summary
The present invention relates to: a composition for preventing or treating a stroke and a food composition for preventing or alleviating a stroke, the compositions containing sobrerol; and the like. The present invention contains, as an active ingredient, sobrerol or a pharmaceutically acceptable salt thereof to have a brain protection effect against ischemic brain tissue damage caused by middle cerebral artery occlusion/reperfusion, and reduces the size of an infarction in the internal capsule, and thus can be effectively usable in the pharmaceutical and food fields for preventing, alleviating, or treating a stroke.